Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...

Please provide your email address to receive an email when new articles are posted on . For patients with obesity, bariatric surgery was more cost-effective than GLP-1 receptor agonists. The biggest ...

Research led by a Northwestern Medicine team found that, despite higher upfront costs, bariatric surgeries offer two more quality years of life compared to GLP-1 therapies. The long-term ...

Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...